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Preoperative chemotherapy for non-small-cell lung cancer: 
a systematic review and meta-analysis of individual 
participant data
NSCLC Meta-analysis Collaborative Group*
Summary
Background Individual participant data meta-analyses of postoperative chemotherapy have shown improved survival 
for patients with non-small-cell lung cancer (NSCLC). We aimed to do a systematic review and individual participant 
data meta-analysis to establish the eﬀ ect of preoperative chemotherapy for patients with resectable NSCLC.
Methods We systematically searched for trials that started after January, 1965. Updated individual participant data were 
centrally collected, checked, and analysed. Results from individual randomised controlled trials (both published and 
unpublished) were combined using a two-stage ﬁ xed-eﬀ ect model. Our primary outcome, overall survival, was deﬁ ned 
as the time from randomisation until death (any cause), with living patients censored on the date of last follow-up. 
Secondary outcomes were recurrence-free survival, time to locoregional and distant recurrence, cause-speciﬁ c survival, 
complete and overall resection rates, and postoperative mortality. Prespeciﬁ ed analyses explored any variation in eﬀ ect 
by trial and patient characteristics. All analyses were by intention to treat.
Findings Analyses of 15 randomised controlled trials (2385 patients) showed a signiﬁ cant beneﬁ t of preoperative 
chemotherapy on survival (hazard ratio [HR] 0·87, 95% CI 0·78–0·96, p=0·007), a 13% reduction in the relative 
risk of death (no evidence of a diﬀ erence between trials; p=0·18, I²=25%). This ﬁ nding represents an absolute 
survival improvement of 5% at 5 years, from 40% to 45%. There was no clear evidence of a diﬀ erence in the eﬀ ect 
on survival by chemotherapy regimen or scheduling, number of drugs, platinum agent used, or whether 
postoperative radiotherapy was given. There was no clear evidence that particular types of patient deﬁ ned by age, 
sex, performance status, histology, or clinical stage beneﬁ ted more or less from preoperative chemotherapy. 
Recurrence-free survival (HR 0·85, 95% CI 0·76–0·94, p=0·002) and time to distant recurrence (0·69, 0·58–0·82, 
p<0·0001) results were both signiﬁ cantly in favour of preoperative chemotherapy although most patients included 
were stage IB–IIIA. Results for time to locoregional recurrence (0·88, 0·73–1·07, p=0·20), although in favour of 
preoperative chemotherapy, were not statistically signiﬁ cant.
Interpretation Findings, which are based on 92% of all patients who were randomised, and mainly stage IB–IIIA, 
show preoperative chemotherapy signiﬁ cantly improves overall survival, time to distant recurrence, and recurrence-
free survival in resectable NSCLC. The ﬁ ndings suggest this is a valid treatment option for most of these patients. 
Toxic eﬀ ects could not be assessed.
Funding Medical Research Council UK.
Copyright © NSCLC Meta-analysis Collaborative Group. Open Access article distributed under the terms of CC BY.
Introduction
Worldwide, roughly 1·5 million new cases of lung cancer 
are diagnosed annually1 with about 85% being non-
small-cell lung cancers (NSCLCs).2 Surgery is thought 
the best treatment option, but only about 20–25% of 
tumours are suitable for potentially curative resection.3 
Two individual participant data meta-analyses4 showed 
that postoperative chemotherapy, with or without 
radiotherapy, improved survival.
Preoperative chemotherapy has the potential to reduce 
tumour size, increase operability, and eradicate micro-
metastases. Chemotherapy might also be more eﬀ ective 
when the blood supply to the tumour is still intact before 
surgical resection, and chemotherapy might be better 
tolerated if patients are not recovering from major surgery. 
However, preoperative chemotherapy will delay surgery, 
and if ineﬀ ective, tumours can become unresectable.
The ﬁ ndings of several reviews, based on aggregate 
data from randomised controlled trials,5–9 have suggested 
preoperative chemotherapy improves survival. However, 
these reviews all included diﬀ erent combinations of 
trials, some of which were confounded by the use of 
chemotherapy in both arms or radiotherapy in one arm, 
making the speciﬁ c eﬀ ects of preoperative chemotherapy 
diﬃ  cult to discern. Furthermore, analyses of other 
outcomes and how eﬀ ects vary by patient characteristics 
were not possible with the aggregate data. Therefore, we 
did a systematic review and meta-analysis of individual 
participant data to provide more reliable and up-to-date 
evidence on the eﬀ ect of preoperative chemotherapy on 
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survival and other key outcomes and whether this varies 
by patient subgroup.
Methods
Design and study selection
Methods were prespeciﬁ ed in a protocol (available on 
request). Randomised trials comparing chemotherapy 
with subsequent surgery versus surgery alone were 
eligible if they started after Jan 1, 1965, and aimed to 
include chemotherapy-naive NSCLC patients, suitable 
for surgery, without any previous malignancy. Trials that 
planned to use postoperative radiotherapy in both arms, 
or postoperative chemotherapy in the preoperative arm 
only, were also eligible.
Published and unpublished trials were sought, with no 
language restrictions, using randomised trial search 
ﬁ lters for Medline and Embase10 with additional terms 
for NSCLC and chemotherapy. These searches were 
supplemented by searching trial registers, conference 
proceedings, review articles, and reference lists of trial 
publications (appendix). Collaborators were asked if they 
knew of any additional trials. Searches were regularly 
updated until May, 2013.
Data collection
For all eligible trials and all patients who were randomised, 
data were sought on the date of randomisation, treatment 
allocation, type of chemotherapy and number of cycles, 
age, sex, histology, performance status, date of surgery, 
extent of resection, clinical and pathological tumour 
stage, clinical and pathological response, recurrence, 
survival, cause of death, and date of last follow-up. 
Standard methods were used to identify missing data and 
to assess data validity and consistency.11 Patterns of 
treatment allocation and the balance of baseline 
characteristics by treatment group were used to check 
randomisation integrity and follow-up of surviving 
patients was checked to ensure it was up to date and 
balanced by arm and fed into a risk of bias assessment for 
each trial.12 Any inconsistencies were resolved and the 
ﬁ nal dataset veriﬁ ed by the relevant trial contact.
Deﬁ nition of outcomes
Our primary outcome, overall survival, was deﬁ ned as 
the time from randomisation until death (any cause), 
with living patients censored on the date of last follow-
up. Secondary outcomes were recurrence-free survival, 
time to locoregional and distant recurrence, cause-
speciﬁ c survival, complete and overall resection rates, 
and postoperative mortality. There were concerns that for 
patients receiving their surgery immediately in the 
surgery-alone arm, any recurrences could be identiﬁ ed 
sooner than in the preoperative chemotherapy arm. This 
might erroneously suggest a beneﬁ t of chemotherapy. 
Thus, analyses of recurrence outcomes were calculated 
from a landmark time of 6 months from the date of 
randomisation to allow for all patients to have completed 
their allocated treatment.13 Events arising within 
6 months of randomisation were regarded as events at 
this landmark time. Recurrence-free survival was deﬁ ned 
as time from the landmark date until locoregional 
recurrence, distant recurrence, or death, whichever 
happened ﬁ rst. Patients alive without recurrence were 
censored on the date of last follow-up. To avoid bias from 
under-reporting of subsequent events, time to 
locoregional (distant) recurrence was deﬁ ned as time 
from the landmark date to ﬁ rst locoregional (distant) 
recurrence, and patients experiencing previous distant 
(local) recurrences were censored on the date of distant 
(local) recurrence. Patients experiencing a locoregional 
and distant recurrence on the same date were counted in 
both analyses. For trials that only recorded the ﬁ rst 
recurrence, patients having a local (distant) recurrence 
were censored in the analysis of distant (local) recurrence; 
all other patients without recurrence were censored on 
the date of death or last follow-up.
We used data on cause of death to assess the eﬀ ects of 
chemotherapy on lung and non-lung cancer survival. 
However, although eight trials supplied these data, only 
two provided suﬃ  ciently detailed information to 
discriminate between treatment-related and other non-
cancer causes, making it impossible to deﬁ ne these 
outcomes accurately.
The overall resection rate was deﬁ ned as the proportion 
of patients having either a complete or incomplete 
resection. The complete resection rate was deﬁ ned as the 
proportion of patients having a complete resection. 
Postoperative mortality was deﬁ ned as the proportion of 
patients dying within 30 days of surgery, and early 
mortality was deﬁ ned as death within 6 months of date of 
randomisation, to allow for completion of all treatment 
in each arm.
Statistical analysis
Unless otherwise stated, all analyses were prespeciﬁ ed in 
the protocol, and done on an intention-to-treat basis. For 
time-to-event outcomes, we used the log-rank expected 
number of events and variance to calculate hazard ratio 
(HR) estimates of eﬀ ect for each individual trial, which 
were then combined across trials using a stratiﬁ ed-by-
trial, two-stage, ﬁ xed-eﬀ ect model.14 The random-eﬀ ects 
model15 was used to assess the robustness of the results. 
χ² heterogeneity tests were used to assess diﬀ erences in 
the eﬀ ect of treatment or treatment by covariate 
interactions across trials. Results for time-to-event 
outcomes are also presented as non-stratiﬁ ed Kaplan-
Meier curves.16 The median follow-up was computed for 
all patients using the reverse Kaplan-Meier method.17 For 
dichotomous outcomes, such as resection rate, the 
numbers of events and patients were used to calculate 
Peto odds ratio (OR) estimates of eﬀ ect14 for trials, which 
were then pooled across trials, using a ﬁ xed-eﬀ ect model.
To explore any eﬀ ect of trial-level characteristics on the 
eﬀ ect of chemotherapy, pooled HRs were calculated for 
See Online for appendix
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each prespeciﬁ ed trial group. χ² tests for interaction and 
the F ratio were used to assess diﬀ erences in treatment 
eﬀ ect across trial groups. To investigate the eﬀ ect of 
patient characteristics on the eﬀ ect of chemotherapy, the 
relevant treatment by patient covariate interaction term 
was included in a Cox regression for each trial. The 
resulting within-trial interactions (HRs) were then 
pooled across trials using the stratiﬁ ed-by-trial, ﬁ xed-
eﬀ ect model.18 These analyses are focused on the primary 
outcome of survival.
Accrual 
years
Number 
of 
patients
Clinical 
stage
Preoperative chemotherapy used (dose per cycle) Postoperative 
chemotherapy 
cycles planned
Postoperative 
radiotherapy 
planned
Reached 
target 
accrual
Stopping reason Median 
follow-up 
(years)
France 199020 1985–87 26 I–III Cyclophosphamide (600 mg/m²), vindesine 
(3 mg/m²), cisplatin (100 mg/m²); 2 cycles every 
4 weeks
2 No No High progression rate 
with preoperative 
chemotherapy
3·2
MD Anderson 
199421
1987–93 60 IIIA Cyclophosphamide (500 mg/m²; d1), etoposide 
(100 mg/m²; d1–3), cisplatin (100 mg/m²; d1); 
3 cycles every 4 weeks
3 to responders Yes, if surgery 
incomplete or 
unresectable
No Beneﬁ t of 
preoperative 
chemotherapy
6·7
Spain 199422 1989–91 59 IIIA Mitomycin (6 mg/m²), ifosfamide (3 g/m²), cisplatin 
(50 mg/m²); 3 cycles every 3 weeks
0 Yes No Beneﬁ t of 
preoperative 
chemotherapy
6·3
MIP-9123 1991–97 355 I–IIIA Mitomycin (6 mg/m², d1), Ifosfamide (1·5 g/m², 
d1–3), cisplatin (30 mg/m², d1–3); 2 cycles every 
3 weeks
2 to responders Yes, if surgery 
incomplete or 
pT3 or pN2
Yes NA 12·9
SWOG S901538 1992–94 21 I–IIIA Etoposide (80 mg/m²; d1–3), carboplatin 
(350 mg/m²; d1); 2 cycles every 3 weeks
3 to responders No No Poor accrual 6·3
JCOG 920924 1993–98 62 IIIA Vindesine (3 mg/m²; d1,8), cisplatin (80 mg/m²; d1); 
3 cycles every 4 weeks
0 Yes, if surgery 
incomplete
No Poor accrual 5·7
Netherlands 
200025
1994–99 79 IB–II Paclitaxel (175 mg/m²; d1), carboplatin (AUC=7; d1); 
or teniposide (120 mg/m²; d1–3), cisplatin 
(80 mg/m²; d1); at least 2 cycles every 3 weeks
0 No No Poor accrual 2·2
Finland 200326 1995–99 62 III Docetaxel (100 mg/m²; d1); 3 cycles every 3 weeks 0 No No Poor accrual 3·1
MRC BLT27 1995–2001 10 I–III Vindesine (3 mg/m²; d1,8), cisplatin (80 mg/m²; d1); 
or vinorelbine (30 mg/m²; d1,8), cisplatin (80 mg/m²; 
d1); or mitomycin (6 mg/m²; d1), ifosfamide (3 g/m²; 
d1), cisplatin (50 mg/m²; d1); or mitomycin 
(6 mg/m²; d1), vinblastine (6 mg/m²; d1), cisplatin 
(50 mg/m²; d1); number of cycles/interval unknown
0 Yes No Poor accrual 3·9
MRC LU2228 1997–2005 519 I–III Mitomycin (8 mg/m²; ﬁ rst 2 cycles only), vinblastine 
(6 mg/m²; max 10 mg), cisplatin (50 mg/m²); or 
mitomycin (8 mg/m²; ﬁ rst 2 cycles only), ifosfamide 
(3 g/m²), cisplatin (50 mg/m²); or vinorelbine 
(30 mg/m²; d1,8; max 60 mg), cisplatin (80 mg/m²; 
d1); or paclitaxel (175 mg/m²), carboplatin (AUC=5); 
or gemcitabine (1250 mg/m²; d1,8), cisplatin 
(80 mg/m²; d1); or docetaxel (75 mg/m²), 
carboplatin (AUC=6); 3 cycles every 3 weeks
0 Yes, if surgery 
incomplete or 
progression
Yes NA 7·6
SWOG S990029 1999–2004 354 IB–IIIA Paclitaxel (225 mg/m²), carboplatin (AUC=6); 
3 cycles every 3 weeks
0 No No Positive results 
of adjuvant 
chemotherapy trials
5·5
China 200230 1999–2004 55 IIIA Docetaxel (75 mg/m²; d1), carboplatin (AUC=5; d1); 
2 cycles every 3 weeks
0 Yes, if surgery 
incomplete
No Positive results 
of adjuvant 
chemotherapy trials/
poor accrual
7·8
China 200531 1999–2004 40 IIIA Gemcitabine (1200–1250 mg/m²; d1,8), cisplatin 
(30 mg/m²; d1–3); or gemcitabine 
(1200–1250 mg/m²; d1,8), carboplatin (AUC=5; 
d1); 2 cycles every 3 weeks
2 to responders No No Poor accrual 3·3
ChEST32 2000–04 270 IB–IIIA Gemcitabine (1250 mg/m²; d1,8), cisplatin 
(75 mg/m²; d1); 3 cycles every 3 weeks
0 No No Positive results 
of adjuvant 
chemotherapy trials
3·10
NATCH33 2000–07 413 IA-IIIA Paclitaxel (200 mg/m²), carboplatin (AUC=6); 
3 cycles every 3 weeks
0 Yes, if 
pathological 
pN2
Yes NA 4·8
NA=not applicable. AUC=area under the curve.
 Table 1: Trial characteristics
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Absolute diﬀ erences in outcome at 5 years were 
calculated from the HR and the control group baseline 
event rate.19 All p values are two-sided.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
We identiﬁ ed 19 eligible randomised controlled trials; 
17 published20–36 and two unpublished 37,38 (appendix). 
Data could not be supplied for three trials,34–36 and one 
trial only recruited two patients.37 Although data were 
obtained for all 24 patients excluded from the 
investigators’ original analyses, and reinstated in this 
meta-analysis, data for two other patients could not be 
obtained. Therefore, this meta-analysis is based on data 
from 15 trials20–33,38 (2385 patients), representing 92% of 
patients who were randomised, from all known eligible 
trials. Any risk of bias associated with the randomisation 
procedure and completeness of outcome data in these 
15 trials was judged to be low and the eﬀ ects of early 
stopping were minimised by the collection of updated 
follow-up and investigated in the analyses.
Ten trials22,24–30,32,33 gave chemotherapy only preoperatively 
and ﬁ ve trials20,21,23,31,38 used chemotherapy preoperatively 
and then postoperatively, usually to responders. All trials 
used platinum-based chemotherapy, except one,26 which 
used docetaxel alone (table 1). Seven trials20–24,27,32 used 
cisplatin, four29,30,33,38 carboplatin, and three25,28,31 either 
cisplatin or carboplatin. Eight trials21–24,27,28,30,33 used post-
operative radiotherapy in both arms.
Data on age, sex, histology, and stage were provided for 
all but one trial,20 and performance status for 11 trials 
(table 2).21,23,25–30,32,33,38 Based on the available data, patients 
were mostly men (80%) with a median age of 62 years 
(IQR 55–68) and good performance status (88%). They 
had mainly clinical stage IB–IIIA tumours (93%) that 
were predominantly squamous cell carcinomas (50%) or 
adenocarcinomas (29%). The median follow-up of all 
patients was 6 years (IQR 4·2–8·2; table 1).
Survival results were based on 15 randomised controlled 
trials (2385 patients, 1427 deaths) and show a clear beneﬁ t 
of preoperative chemotherapy (HR 0·87, 95% CI 
0·78–0·96; p=0·007; ﬁ gures 1, 2). This represents a 13% 
reduction in the relative risk of death, translating to a 5% 
absolute improvement in survival at 5 years (from 40% to 
45%). Despite design diﬀ erences between trials, for 
example, a variety of chemotherapy regimens, exclusive 
use of preoperative chemotherapy, use of postoperative 
radiotherapy in both arms, and inclusion of all stages of 
patients or only a speciﬁ c stage of patient, there was no 
clear evidence of statistical heterogeneity (p=0·18).
There is no clear evidence that the eﬀ ect of 
chemotherapy on survival diﬀ ered according to whether 
chemotherapy was given preoperatively or both 
preoperatively and postoperatively (interaction p=0·23), 
the number of preoperative chemotherapy cycles 
(interaction p=0·68), the type of chemotherapy regimen 
(interaction p=0·94), the number of chemotherapy agents 
per regimen (interaction p=0·84), or both the type of 
chemotherapy regimen and number of agents (interaction 
p=0·79; table 3). Analyses of the type of regimen, the 
number of agents per regimen, and both the type of 
regimen and number of agents were repeated only in 
those trials that gave platinum-based regimens, and gave 
similar results (interactions p=0·91, p=0·60, and p=0·62 
respectively; table 3). We did not identify evidence of a 
diﬀ erence in eﬀ ect of chemotherapy on survival by 
whether regimens were cisplatin or carboplatin-based 
(interaction p=0·48) or whether postoperative 
radiotherapy was used (interaction p=0·87; table 3).
Surgery Chemotherapy 
plus surgery
Age, years
<60 450 (38%) 486 (42%)
60–64 239 (20%) 202 (17%)
65–69 259 (22%) 251 (22%)
≥70 244 (20%) 224 (19%)
Unknown 2 (<1%) 2 (<1%)
Sex
Male 970 (81%) 918 (79%)
Female 221 (19%) 244 (21%)
Unknown 3 (<1%) 3 (<1%)
Histology
Adenocarcinoma 353 (29%) 327 (28%)
Squamous 616 (52%) 573 (49%)
Large cell 49 (4%) 78 (7%)
Other 162 (14%) 176 (15%)
Unknown 14 (1%) 11 (1%)
Clinical stage
IA 63 (5%) 71 (6%)
IB 545 (46%) 501 (43%)
IIA 21 (2%) 29 (3%)
IIB 309 (26%) 278 (24%)
IIIA 246 (21%) 270 (24%)
IIIB 4 (<1%) 9 (<1%)
IV 0 (<1%) 3 (<1%)
Unknown 6 (<1%) 4 (<1%)
Performance status
0 471 (43%) 463 (43%)
1 514 (46%) 494 (45%)
2+ 123 (11%) 125 (12%)
Unknown 4 (<1%) 4 (<1%)
Data are n (%). Data for all characteristics, except performance status, were 
available for 14 of the 15 trials (99% of all patients). For performance status, 
data were available for 11 of the 15 trials (92% of all patients).
Table 2: Characteristics of included patients
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Although the interaction test is not signiﬁ cant there is 
some suggestion of a larger relative eﬀ ect in trials where 
postoperative chemotherapy is given to responders 
(HR 0·78, 95% CI 0·64–0·95, p=0·02) than in those 
giving preoperative chemotherapy alone. Exploratory 
analyses examining whether such an approach modiﬁ es 
the eﬀ ect of chemotherapy on time to local recurrence 
showed a similar pattern (preoperative chemotherapy 
HR 0·94, 95% CI 0·75–1·18, p=0·60; preoperative plus 
postoperative chemotherapy HR 0·73, 95% CI 0·50–1·07, 
p=0·11), but again no clear evidence of an interaction 
(p=0·26). However, for time to distant recurrence, there 
is evidence of a diﬀ erence in eﬀ ect by chemotherapy 
scheduling (p=0·05), with a substantially greater relative 
beneﬁ t in trials giving postoperative chemotherapy 
(HR 0·53, 95% CI 0·39–0·73, p<0·001) than in those 
using just preoperative chemotherapy (HR 0·78, 95% CI 
0·63–0·96, p=0·02).
12 trials did not reach their target accrual. Two21,22 closed 
early after recording a beneﬁ t of chemotherapy, one20 due to 
high progression rates in the chemotherapy arm, six due to 
poor accrual24–27,31,38 and three due to positive results in 
postoperative chemotherapy trials.29,30,32 Based on all trials, 
although we found some evidence of a diﬀ erence in eﬀ ect 
by the reason for early stopping of trials, small trials with 
extreme positive and negative estimates seem to strongly 
aﬀ ect this result (table 3). An exploratory analysis, excluding 
smaller trials (100 patients or fewer), was based on 80% of 
the data (77% of all deaths),23,28,29,32,33 and showed no clear 
diﬀ erence in eﬀ ect between trials stopping early and those 
reaching their target accrual (interaction p=0·24).
Figure 1: Eﬀ ect of preoperative chemotherapy on survival
Each square denotes the HR for that trial comparison with the horizontal lines showing the 95% and 99% CIs. The size of the square is directly proportional to the 
amount of information contributed by the trial. The black diamond gives the pooled HR from the ﬁ xed eﬀ ect model; the centre of this diamond denotes the HR and 
the extremities the 95% CI. O–E=observed minus expected. HR=hazard ratio. MIP=mitomycin, ifosphamide, cisplatin. SWOG=South West Oncology Group. 
JCOG=Japanese Cancer Oncology Group. MRC=Medical Research Council. BLT=Big Lung Trial. ChEST=Chemotherapy for Early Stages Trial. NATCH=Neoadjuvant/
Adjuvant Trial of Chemotherapy. df=degrees of freedom. *Number of events/number entered.
Figure 2: Kaplan-Meier curves (non-stratiﬁ ed) of the eﬀ ect of preoperative chemotherapy on time to survival
France 1990
MD Anderson 1994
Spain 1994
MIP-91
SWOG S9015
JCOG 9209
Netherlands 2000
Finland 2003
MRC BLT
MRC LU22
SWOG S9900
China 2002
China 2005
ChEST
NATCH
Total
Overall HR
0·87 (0·78–0·96). p=0·007 (ﬁxed eﬀect)
0·86 (0·75–0·98), p=0·03 (random eﬀects)
Heterogeneity: χ2=18·75, df=14, p=0·18, I2=25%
0·87 (0·78–0·96); p=0·007
0 0·5 1·0 1·5
Preoperative
chemotherapy
better
Non-preoperative
chemotherapy
better
2·0
 8/13
 19/28
 19/29
 137/179
 3/5
 28/31
 23/39
 19/30
 4/5
 151/258
 93/180
 26/32
 8/19
 45/129
 99/201
 682/1178
Preoperative
chemotherapy*
 8/13
 27/32
 27/30
 146/176
 12/16
 25/31
 15/40
 19/32
 3/5
 158/261
 103/174
 18/23
 14/21
 61/141
 109/212
 745/1207
Control*
 0·32
 –6·40
 –8·88
 –12·99
 –1·04
 2·25
 3·86
 –0·50
 1·26
 –2·92
 –9·31
 1·42
 –3·31
 –10·27
 –4·11
 –50·62
O–E
 3·97
 11·19
 9·65
 70·22
 2·94
 12·97
 9·36
 9·48
 1·60
 77·01
 48·84
 10·78
 5·44
 26·39
 51·95
 351·78
Variance HR (95% CI); p value
Number at risk
No preoperative
chemotherapy
Preoperative
chemotherapy
0
1207
1178
1
893
928
2
674
712
3
527
570
4
409
442
5
300
346
6
209
253
7
147
172
8
102
123
Time from randomisation (years)
0
0·1
0·2
0·3
0·4
0·5
0·6
0·7
0·8
0·9
1·0
Su
rv
iv
al
HR=0·87, p=0·007
No preoperative chemotherapy
Preoperative chemotherapy
Events
745
682
Totals
1207
1178
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We did not identify clear evidence that the eﬀ ect of 
preoperative chemotherapy on survival diﬀ ered by age, 
age group, performance status, or histology (ﬁ gure 3). 
Although, overall, there is no evidence of a diﬀ erence in 
eﬀ ect by sex, there is heterogeneity in the interaction 
(ﬁ gure 3). Some trials suggest the eﬀ ect might be greater 
in women and others in men, but it is not clear why. Also, 
there was a signiﬁ cant interaction between the eﬀ ect of 
preoperative chemotherapy and stage in the ChEST trial,32 
but not in the other trials, or across all trials (interaction 
p=0·83; appendix). An exploratory analysis, splitting 
clinical stage I disease into IA and IB, also identiﬁ ed an 
interaction between the treatment eﬀ ect and clinical stage 
in the ChEST trial, but not across trials (p=0·64, 
heterogeneity p=0·22). Thus, the overall HR of 0·87 was 
applied to the control group survival for each stage, giving 
an absolute survival improvement at 5 years of 5% for all 
stages, taking it from 50% to 55% in stage I, from 30% to 
35% in stage II, and from 20% to 25% in stage III. 
However, most patients in stage I are IB (89%), in stage II 
are IIB (92%), and in stage III are IIIA (98%), therefore 
we can be most conﬁ dent of results for these patients.
Mortality within 30 days of surgery could be calculated 
for nine trials,23,25,26,28–32,38 (1611 patients, 52 deaths) that 
Number 
of trials
Number 
of deaths/
patients
Hazard ratio (95%CI),
p value
Hetero-
geneity 
p value
F ratio
p value
Interaction
p value
Survival by planned chemotherapy schedule (n=15 trials) 0·32 0·23
Preoperative chemotherapy only 10 1045/1883 0·90 (0·80–1·02), 0·09 0·10
Preoperative and postoperative chemotherapy (to 
responders)
5 382/502 0·78 (0·64–0·95), 0·02 0·62
Survival by number of preoperative chemotherapy cycles (n=14 trials) 0·74 0·68
2 cycles 6 418/576 0·89 (0·74–1·08), 0·25 0·39
3 cycles 8 1002/1799 0·85 (0·75–0·96), 0·01 0·10
Survival by chemotherapy regimen (n=14 trials) 0·96 (all trials), 0·94 
(platinum-only trials)
0·95 (all trials), 0·91 
(platinum-only trials)
Platinum plus second generation chemotherapy 7 543/694 0·86 (0·72–1·02), 0·08 0·03
Platinum plus third generation chemotherapy 6 801/1540 0·85 (0·74–0·97), 0·02 0·57
Non-platinum chemotherapy 1 38/62 0·95 (0·50–1·79), 0·87 NA
Survival by the number of chemotherapy agents (n=15 trials) 0·90 (all trials), 0·70 
(platinum-only trials)
0·84 (all trials), 0·60 
(platinum-only trials)
Non platinum single agent regimen 1 38/62 0·95 (0·50–1·79), 0·87 NA
Doublet regimen 9 907/1702 0·88 (0·78–1·01), 0·06 0·42
Triplet regimen 5 475/611 Fixed eﬀ ect 0·83 (0·69–1·00), 
0·05; random eﬀ ects 0·79 
(0·53–1·18), 0·25
0·01
Survival by chemotherapy regimen and number of chemotherapy agents (n=14 trials) 0·89 (all trials), 0·95 
(platinum-only trials)
0·79 (all trials), 0·62 
(platinum-only trials)
Non-platinum single agent regimen 1 38/62 0·95 (0·50–1·79), 0·87 NA
Platinum second generation, doublet 2 68/83 1·08 (0·66–1·76), 0·76 0·42
Platinum second generation, triplet 5 475/611 Fixed eﬀ ect 0·83 (0·69–1·00), 
0·05; random eﬀ ects 0·79 
(0·53–1·18), 0·25
0·01
Platinum third generation, doublet 6 801/1540 0·85 (0·74–0·97), 0·02 0·57
Survival by cisplatin or carboplatin regimen (n=12 trials) 0·54 0·48
Cisplatin-based 7 830/1289 0·83 (0·72–0·95), 0·01 0·08
Carboplatin-based 5 492/905 0·90 (0·75–1·07), 0·23 0·88
Survival by planned postoperative radiotherapy (n=15 trials) 0·64 0·57
No postoperative radiotherapy given 8 431/852 0·83 (0·68–1·00), 0·05 0·40
Postoperative radiotherapy given 7 996/1533 0·88 (0·78–1·00), 0·05 0·09
Survival by whether trial stopped early (all trials; n=15 trials) 0·10 0·05
Reached target accrual 3 800/1287 0·90 (0·79–1·04), 0·16 0·66
Stopped for beneﬁ t of chemotherapy 2 92/119 0·48 (0·31–0·74), <0·001 0·43
Stopped for high progression on chemotherapy arm 1 16/26 1·08 (0·41–2·90), 0·87 NA
Stopped for poor accrual/positive adjuvant trials 9 519/953 0·88 (0·74–1·05), 0·17 0·31
NA=not applicable.
Table 3: Eﬀ ect of preoperative chemotherapy by prespeciﬁ ed trial group
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supplied date of surgery. Four of these26,30,31,38 had no 
deaths within 30 days of surgery in either arm and an OR 
was not estimable. Overall, we did not identify a 
diﬀ erence between treatment arms (OR 1·48, 95% CI 
0·85–2·58, p=0·17; heterogeneity p=0·45, appendix). 
Based on all 15 trials (2381 patients, 254 deaths), we also 
did not identify a deleterious eﬀ ect of preoperative 
chemotherapy on mortality within 6 months of 
randomisation (OR 0·88, 95%CI 0·67–1·14, p=0·33; 
heterogeneity p=0·60).
11 trials21,23–26,28–32,38 (1778 patients) provided data on 
extent of resection. For the overall resection rate, ORs 
could not be estimated for four trials21,23,29,31 because they 
had 100% resection rates in both arms. The remaining 
seven trials24–26,28,30,32,38 represented less than half of the 
total data and, with possible variation in the classiﬁ cation 
of extent of incomplete resection, this analysis was 
deemed unreliable. Based on all 11 trials, there was no 
evidence of an eﬀ ect of preoperative chemotherapy on 
complete resection (OR 0·88, 95% CI 0·68–1·14, 
p=0·33; appendix), but the eﬀ ect did vary between trials 
(heterogeneity p=0·006). This variation might relate to 
diﬀ erences in the types of patients or surgery, because 
the baseline complete resection rate for control patients 
ranged from 67% to 95%, with the exception of one 
trial21 where it was substantially lower (31%).
Recurrence-free survival data were available for 
14 trials20,21,23–33,38 (2326 patients, 1524 events). The ﬁ ndings 
provide clear evidence of a beneﬁ t of preoperative 
chemotherapy (HR 0·85, 95% CI 0·76–0·94, p=0·002, 
heterogeneity p=0·41, ﬁ gure 4), translating to an absolute 
improvement in recurrence-free survival of 6% at 5 years, 
taking it from 30% to 36%.
Data on both time to locoregional recurrence and 
distant recurrence were available for 13 trials20,21,23–32,38 and 
1913 patients (426 events and 526 events respectively). In 
these patients, 630 (33%) were alive and free from 
disease. For the remaining 1283 patients, the ﬁ rst events 
recorded were locoregional recurrence for 305 (24%), 
distant recurrence for 397 (31%), both locoregional and 
distant recurrence for 115 (9%), and death without 
recurrence for 466 (36%; appendix). There is clear 
evidence of a beneﬁ t of preoperative chemotherapy on 
time to distant recurrence (HR 0·69, 95% CI 0·58–0·82; 
p<0·001; heterogeneity p=0·40; ﬁ gure 4), but the eﬀ ect 
on time to locoregional recurrence was less clear 
(HR 0·88, 95% CI 0·73–1·07; p=0·20; heterogeneity 
p=0·89; ﬁ gure 4). These ﬁ ndings translate into an 
absolute improvement in time to distant recurrence of 
10% at 5 years (from 60% to 70%). There is a potential 
improvement on time to locoregional recurrence of 3% 
at 5 years.
Figure 3: Forest plot of the interactions between the eﬀ ect of preoperative chemotherapy on survival and covariates
The circles represent (ﬁ xed eﬀ ect) meta-analyses of the HRs representing the interactions between the eﬀ ect of chemotherapy and patient characteristics; the 
horizontal line shows the 95% CI. HR=hazard ratio.
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Discussion
Based on data from 15 randomised trials (92% of all 
patients who were randomised), we have shown a 5% 
absolute beneﬁ t of preoperative chemotherapy on 5 year 
survival in patients with resectable NSCLC. There was no 
clear evidence of a diﬀ erence in this eﬀ ect by treatment 
type, scheduling, trial design diﬀ erences, or by patient 
characteristics, although the results are most reliable for 
stage IB–IIIA. There seemed to be no excess of early 
mortality in the preoperative chemotherapy arm as a 
result of deferred surgery.
Although this meta-analysis included most patients 
known to have been randomised, four eligible trials 
(198 patients) could not be included. We could estimate 
an HR39 for survival for one trial of 90 patients,36 but not 
the remaining three trials. Two of these34,35 (106 patients) 
did not report the appropriate information, and one (two 
patients) was unpublished.37 When the single estimated 
HR was combined with the overall result for the 
meta-analysis, the eﬀ ect on survival remained the same 
(HR 0·87, p=0·006), but being based on 96% of patients 
who were randomised, it provides more convincing 
evidence of a beneﬁ t of preoperative chemotherapy. This 
systematic review and meta-analysis will be updated if 
further eligible trials are identiﬁ ed.
One reason for using preoperative chemotherapy is 
that it might make tumours more operable, potentially 
improving the likelihood of a complete resection. 
Conversely, delays to surgery could make it harder to 
achieve a complete resection. However, we did not 
identify clear evidence of a positive or negative eﬀ ect of 
chemotherapy on the complete resection rate or a beneﬁ t 
on locoregional recurrence. However, we did note a 10% 
absolute beneﬁ t of preoperative chemotherapy on distant 
recurrence at 5 years, suggesting that it might have 
greater potential to eradicate micrometastases than 
postoperative chemotherapy, where the absolute beneﬁ t 
was 5% at 5 years.4
Comparing the eﬀ ect of preoperative and postoperative 
chemotherapy directly, using data from this meta-analysis 
and two previous ones of postoperative chemotherapy in 
NSCLC proved problematic. Although it was possible to 
make the datasets comparable in terms of the regimens 
used, we could not make them comparable in terms of 
their patient characteristics, particularly stage. Only 
pathological stage was available for the postoperative 
chemotherapy meta-analysis, and agreement between 
clinical and pathological staging in the control group 
patients of the current meta-analysis was only around 
60%. However, survival in the control group of the present 
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Figure 4: Kaplan-Meier curves (non-stratiﬁ ed) of the eﬀ ect of preoperative chemotherapy on time to distant and locoregional recurrence and recurrence-free 
survival
Analyses of recurrence outcomes were calculated from a landmark time of 6 months from the date of randomisation; for this reason time on the x-axis starts at 6 months.
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meta-analysis is somewhere between that noted for 
patients receiving surgery alone and those receiving 
surgery plus radiotherapy as deﬁ nitive treatment,4 
suggesting that the present population spans the two. 
Although this diﬀ erence makes a formal indirect 
comparison of the eﬀ ects of preoperative and 
postoperative chemotherapy diﬃ  cult, the beneﬁ t noted is 
on a similar scale. Others have attempted formal 
comparison based on aggregate data8 and concluded the 
eﬀ ect of chemotherapy on overall or recurrence-free 
survival is similar, irrespective of chemotherapy timing. 
However, they did not include key large trials, published 
more recently, and have included a trial confounded by 
the use of radiotherapy in only one arm.40
We included one three-arm trial (NATCH33) with both 
preoperative and postoperative chemotherapy arms, but 
because it was underpowered, the authors did not report 
their direct comparison. Nevertheless, they provided us 
with analyses showing similar eﬀ ects of preoperative and 
postoperative chemotherapy on survival (HR 0·93, 
95% CI 0·71–1·23, p=0·61) and recurrence-free survival 
(HR 0·88, 95% CI 0·68–1·13, p=0·31; Rosell R, 
unpublished). Similarly, a recent trial41 (198 patients), of 
preoperative versus postoperative chemotherapy reported 
no diﬀ erence in disease-free survival (HR 0·88, 95% CI 
0·58–1·33, p=0·54), although power could also be an 
issue in this trial.
The ﬁ ndings of NATCH33 showed a diﬀ erence in 
treatment compliance between the preoperative (90%) 
and the postoperative (60%) chemotherapy arms. Of the 
trials included in our report, the ten20,22–26,28,29,32,33 that 
reported the number of patients receiving all scheduled 
preoperative chemotherapy (2–3 cycles), identiﬁ ed a 
similarly high compliance rate with preoperative 
chemotherapy (mean compliance rate 85%, 
range 71–100%). By contrast, for the 14 trials in the 
postoperative chemotherapy systematic review4 that 
reported patients receiving scheduled chemotherapy 
(2–6 cycles), the mean compliance rate was somewhat 
lower (62%, range 41–98%). This implies that patients 
might receive more of their planned chemotherapy if it is 
given before surgery.
The results so far seem to suggest similar eﬀ ects with 
either preoperative or postoperative chemotherapy, 
giving a choice of treatment options. Clinicians might 
consider that preoperative chemotherapy is preferable 
for poorer prognosis patients with larger, more advanced 
stage tumours, less able to tolerate chemotherapy after 
surgery, or in regions where surgery waiting lists are 
longer. Postoperative chemotherapy might be preferred 
by surgeons and by patients wishing to have potentially 
curative treatment immediately, or for those with earlier 
stage disease. It also allows for more reliable pathological 
staging to establish if subsequent chemotherapy is 
appropriate.
Because this meta-analysis shows that preoperative 
chemotherapy has a greater eﬀ ect on metastases, and a 
previous one4 shows that postoperative chemotherapy 
has a greater eﬀ ect on local control, it is tempting to 
speculate that combined preoperative and postoperative 
chemotherapy would confer a greater beneﬁ t on local 
and distant control and survival. This is not entirely 
borne out by the present survival results by chemotherapy 
scheduling and generally only those patients responding 
to preoperative chemotherapy were also given 
postoperative chemotherapy such that most would have 
received preoperative chemotherapy alone. However, 
exploratory analyses do suggest a synergistic eﬀ ect of 
combining preoperative and postoperative chemotherapy 
on time to metastases. However, it should be noted that 
more cycles of chemotherapy were planned in the trials 
of combined preoperative and postoperative 
chemotherapy (2–3 plus 2–3 cycles postoperatively) 
compared with those of just preoperative chemotherapy 
(2–3). Moreover, a recently reported trial that compared 
the use of preoperative chemotherapy plus postoperative 
chemotherapy42 to responders with postoperative 
chemotherapy in 528 similar patients identiﬁ ed no 
evidence that preoperative plus postoperative 
chemotherapy was better (HR 1·01, 95% CI 0·79–1·30, 
p=0·92). Nevertheless, further head-to-head comparisons 
of these approaches might be warranted.
The potential beneﬁ t of preoperative chemotherapy 
would need to be balanced against possible toxic eﬀ ects. 
However, although we were unable to assess toxic eﬀ ects 
at the patient level in this study, trial reports for 13 of the 
included trials described mild or acceptable toxic eﬀ ects 
and that chemotherapy was generally well tolerated. 
Further questions regarding which drugs to use, the 
duration of chemotherapy, and if the eﬀ ect might be 
modiﬁ ed by predictive genetic biomarkers will need to be 
answered by new or ongoing trials. Nevertheless, these 
results provide the most complete evidence so far of the 
eﬀ ects of preoperative chemotherapy, showing a 
signiﬁ cant improvement in overall survival, time-to-
distant recurrence, and recurrence-free survival.
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